TEL AVIV, ISRAEL, October 26 2006 – Compugen Ltd. (NASDAQ: CGEN) announced today that Martin Gerstel, Chairman of the Board, is scheduled to present at the upcoming Unterberg, Towbin Life Sciences Conference at 11:30 AM (Eastern Time) on Monday, October 30, 2006 at the Palace Hotel in New York City.
A live Webcast of the presentation will be available at http://www.wsw.com/webcast/ceut5/cgen/, and on Compugen’s Website. A replay will be available for 90 days following the presentation.
Compugen’s mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industry. The Company’s powerful discovery engines enable the predictive discovery of numerous potential therapeutics and diagnostic biomarkers. This capability results from the Company’s decade-long pioneering efforts in the deeper understanding of important biological phenomena at the molecular level through the incorporation of ideas and methods from mathematics, computer science and physics into biology, chemistry and medicine. To date, Compugen’s product discovery efforts and its initial discovery engines have focused mainly within the areas of cancer, immune-related and cardiovascular diseases. The Company’s primary commercialization pathway for its therapeutic and diagnostic product candidates is to enter into milestone and revenue sharing out-licensing and joint development agreements with leading companies. Compugen has established an agricultural biotechnology affiliate – Evogene, and a small-molecule drug discovery affiliate – Keddem Bioscience. For additional information, please visit Compugen’s corporate Website at www.cgen.com.